Bli medlem
Bli medlem

Du är här


XBiotech Names Industry Veteran Dawn McCollough to Head Clinical Operations

Head Clinical Operations

AUSTIN, Texas, 2016-05-16 14:00 CEST (GLOBE NEWSWIRE) --
XBiotech (NASDAQ:XBIT), the developer of True Human™ therapeutic antibodies,
today announced that Dawn McCollough has joined the company as Vice President
of Clinical Operations, effective May 16. McCollough has more than two decades
of global industry experience and has overseen all phases of clinical trial
drug development across multiple therapeutic areas.

Reporting to XBiotech Founder, President and Chief Executive Officer John
Simard, McCollough will lead clinical operations for XBiotech’s extensive
portfolio of True Human antibody therapies, including Xilonix™, the Company’s
lead candidate currently in late-stage development for the treatment of
advanced colorectal cancer.

“Dawn has overseen clinical trials involving thousands of patients across
multiple indications and stages of development,” Simard said. “She thus brings
extraordinary experience to our clinical operations. I am delighted to bring
her energy and enthusiasm to the XBiotech leadership team.”

McCollough joins XBiotech from Biogen, Inc., where she served as head of
Medical Research Operations and led the Medical Research team, which included
the company’s Clinical Trial Review Committee. Prior to Biogen, McCollough was
head of the Global Monitoring Organization for North America at Novartis
Vaccines and Diagnostics, Inc., based in Cambridge, Mass. McCollough began her
Novartis career in their Vaccines and Diagnostics division in Siena, Italy, as
Global Head of Clinical Trial Governance. She has been recognized consistently
for her high performance and was chosen as a top Women’s Leader by both

“I am excited to join XBiotech in advancing the Company’s innovative True Human
therapeutic antibodies through the clinical process across multiple therapeutic
areas. My focus will be on demonstrating our commitment to our investigators
and patients in the continued development of potentially groundbreaking new

XBiotech’s lead product candidate, Xilonix, has the potential to change the
standard of care in treating advanced colorectal cancer. Currently in Phase III
clinical trials in the U.S. with Fast Track designation from the U.S. Food and
Drug Administration, Xilonix is specifically designed to target and neutralize
interleukin-1 alpha (IL-1a), a molecule known to promote angiogenesis (the
growth and spread of tumors), as well as mediate symptoms such as metabolic
dysregulation (e.g., a cause of muscle loss and weight loss), fatigue and
anxiety associated with advanced cancer.

About True Human™ Therapeutic Antibodies
Unlike previous generations of antibody therapies, XBiotech’s True Human™
antibodies are 100 percent human, derived from individuals who possess natural
immunity to certain diseases. With discovery and clinical programs across
multiple disease areas, XBiotech’s True Human antibodies have the potential to
harness the body’s natural immunity to fight disease with increased safety,
efficacy and tolerability.

The first of these therapies, Xilonix™, for advanced colorectal cancer, is in
Phase III clinical trials in the United States with a Fast Track designation by
the U.S. Food and Drug Administration (FDA). In Europe, Xilonix Phase III
clinical trials have been completed, and the therapy is under accelerated
review following the validation of its Market Authorization Application by the
European Medicines Agency (EMA).

About XBiotech
XBiotech is a fully integrated global biosciences company dedicated to
pioneering the discovery, development and commercialization of therapeutic
antibodies based on its True Human™ proprietary technology. XBiotech currently
is advancing a robust pipeline of antibody therapies to exceed the standards of
care in oncology, inflammatory conditions and infectious diseases.
Headquartered in Austin, Texas, XBiotech also is leading the development of
innovative biotech manufacturing technologies designed to more rapidly,
cost-effectively and flexibly produce new therapies urgently needed by patients
worldwide. For more information, visit

Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements, including declarations
regarding management's beliefs and expectations that involve substantial risks
and uncertainties. In some cases, you can identify forward-looking statements
by terminology such as "may," "will," "should," "would," "could," "expects,"
"plans," "contemplate," "anticipates," "believes," "estimates," "predicts,"
"projects," "intend" or "continue" or the negative of such terms or other
comparable terminology, although not all forward-looking statements contain
these identifying words. Forward-looking statements are subject to inherent
risks and uncertainties in predicting future results and conditions that could
cause the actual results to differ materially from those projected in these
forward-looking statements. These risks and uncertainties are subject to the
disclosures set forth in the "Risk Factors" section of certain of our SEC
filings. Forward-looking statements are not guarantees of future performance,
and our actual results of operations, financial condition and liquidity, and
the development of the industry in which we operate, may differ materially from
the forward-looking statements contained in this press release. Any
forward-looking statements that we make in this press release speak only as of
the date of this press release. We assume no obligation to update our
forward-looking statements whether as a result of new information, future
events or otherwise, after the date of this press release.

Media liaison U.S.
Mariann Caprino

Media liaison ex-U.S.
Jonathan Kearney
+44 20 8618 2755; Mobile: +44 7725 925 841

Författare SSE

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.